<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Domperidone (United States: Available via FDA investigational drug [IND] protocol only): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Domperidone (United States: Available via FDA investigational drug [IND] protocol only): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Domperidone (United States: Available via FDA investigational drug [IND] protocol only): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11257" href="/d/html/11257.html" rel="external">see "Domperidone (United States: Available via FDA investigational drug [IND] protocol only): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866649"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Domperidone;</li>
<li>BIO-Domperidone;</li>
<li>Domperidone-10;</li>
<li>GMD-Domperidone;</li>
<li>JAMP-Domperidone;</li>
<li>Mar-Domperidone;</li>
<li>PMS-Domperidone [DSC];</li>
<li>Priva-Domperidone [DSC];</li>
<li>PRZ-Domperidone;</li>
<li>TARO-Domperidone;</li>
<li>TEVA-Domperidone</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F162531"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Dopamine Antagonist;</li>
<li>
                        Gastrointestinal Agent, Prokinetic</li></ul></div>
<div class="block doa drugH1Div" id="F162495"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Use the lowest effective dose for the shortest duration necessary.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a776e594-616f-4b46-89c6-7f59d2b43214">GI motility disorders</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>GI motility disorders (diabetic gastroparesis, gastritis):</b>
<b>Oral:</b> 10 mg 3 times daily (maximum: 30 mg/day). The American College of Gastroenterology recommends initiating at 10 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23147521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23147521'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="982c6851-904f-467e-9d20-0e3256b66d03">Nausea/vomiting associated with dopamine-agonist anti-Parkinson agents</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea/vomiting associated with dopamine-agonist anti-Parkinson agents: Oral: </b>10 mg 3 times daily (maximum: 30 mg/day).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991380"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: 10 mg once or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (large V<sub>d</sub>): <b>Oral:</b> 10 mg once or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28843456','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28843456','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (large V<sub>d</sub>): <b>Oral:</b> 10 mg once or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28843456','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28843456','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: Oral: </b>Has not been studied; consider 10 mg once or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b>
<b>Oral:</b> Has not been studied; consider administering 10 mg once or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988562"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Mild impairment: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution (undergoes hepatic metabolism).</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Moderate or severe impairment: Use is contraindicated.</p></div>
<div class="block doe drugH1Div" id="F3062960"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F58073893"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Altered cardiac conduction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Domperidone may cause dose-related QT prolongation and sudden cardiac death observed initially with intravenous doses but also reported with oral administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26117678','lexi-content-ref-27182647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26117678','lexi-content-ref-27182647'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related, related to pharmacologic action. Sudden cardiac death (SCD) results from the evolution of fatal arrhythmias, such as serious ventricular arrythmia (SVA). Drug-induced closure of the human ether a-go-go related gene (HERG) potassium efflux channel on the myocardium leads to the inhibition of the channel and thus the inability to move potassium out of the cell. This delays cardiac repolarization, which prolongs the QT interval and potentially leads to fatal arrythmia (eg, torsades de pointes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26117678','lexi-content-ref-26098410','lexi-content-ref-34617008','lexi-content-ref-27182647','lexi-content-ref-29441683','lexi-content-ref-23188128','lexi-content-ref-20394569','lexi-content-ref-27861438','lexi-content-ref-20925438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26117678','lexi-content-ref-26098410','lexi-content-ref-34617008','lexi-content-ref-27182647','lexi-content-ref-29441683','lexi-content-ref-23188128','lexi-content-ref-20394569','lexi-content-ref-27861438','lexi-content-ref-20925438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; SVA/SCD and QTc prolongation are reported sporadically. Data are based on animal studies, case-control or cohort analysis, and exact exposure prior to the event is often unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26098410','lexi-content-ref-11034933','lexi-content-ref-30720577','lexi-content-ref-20652862','lexi-content-ref-33990364','lexi-content-ref-33439512','lexi-content-ref-27062307','lexi-content-ref-27296864']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26098410','lexi-content-ref-11034933','lexi-content-ref-30720577','lexi-content-ref-20652862','lexi-content-ref-33990364','lexi-content-ref-33439512','lexi-content-ref-27062307','lexi-content-ref-27296864'])">Ref</a></span>). Some data show the highest frequency of SCD with current domperidone use for 8 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Motilium.2021.07']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Motilium.2021.07'])">Ref</a></span>). Consistent with this observation, a single retrospective analysis indicated the highest frequency of SVA/SCD events occurred after the initial domperidone prescription was dispensed, and the event frequency decreased with subsequent prescription refills (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20652862']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20652862'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (&gt;30 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26098410','lexi-content-ref-23188128','lexi-content-ref-33439512','lexi-content-ref-27062307','lexi-content-ref-20925438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26098410','lexi-content-ref-23188128','lexi-content-ref-33439512','lexi-content-ref-27062307','lexi-content-ref-20925438'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of drugs that are known to cause QT prolongation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26117678','lexi-content-ref-27182647','lexi-content-ref-29441683','lexi-content-ref-27062307','lexi-content-ref-20394569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26117678','lexi-content-ref-27182647','lexi-content-ref-29441683','lexi-content-ref-27062307','lexi-content-ref-20394569'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of drugs that can increase serum concentrations of domperidone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26117678','lexi-content-ref-26098410','lexi-content-ref-27182647','lexi-content-ref-29441683','lexi-content-ref-20925438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26117678','lexi-content-ref-26098410','lexi-content-ref-27182647','lexi-content-ref-29441683','lexi-content-ref-20925438'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting or familial history of QT prolongation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26117678','lexi-content-ref-29441683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26117678','lexi-content-ref-29441683'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Electrolyte abnormalities (eg, hypokalemia, hyperkalemia, hypocalcemia, hypomagnesemia, hypoglycemia in the absence of diabetes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26117678','lexi-content-ref-20394569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26117678','lexi-content-ref-20394569'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hepatic dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26117678','lexi-content-ref-26098410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26117678','lexi-content-ref-26098410'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (≥60 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26117678','lexi-content-ref-29441683','lexi-content-ref-27062307','lexi-content-ref-20394569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26117678','lexi-content-ref-29441683','lexi-content-ref-27062307','lexi-content-ref-20394569'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441683','lexi-content-ref-27062307','lexi-content-ref-20394569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441683','lexi-content-ref-27062307','lexi-content-ref-20394569'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441683'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441683','lexi-content-ref-Motilium.2021.07']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441683','lexi-content-ref-Motilium.2021.07'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Status post-syncope or seizures, within the past 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441683'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of chronic kidney failure requiring dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26098410','lexi-content-ref-29441683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26098410','lexi-content-ref-29441683'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21883386','lexi-content-ref-30720577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21883386','lexi-content-ref-30720577'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F162461"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (≤1%), skin rash (≤1%), urticaria (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Galactorrhea not associated with childbirth (≤1%), gynecomastia (≤1%), hot flash (≤1%), increased thirst (≤5%), menstrual disease (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (≤2%), acid regurgitation (≤2%), change in appetite (≤2%), constipation (≤2%), diarrhea (≤2%), dyspepsia (≤2%), nausea (≤2%), stomatitis (≤1%), xerostomia (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Mastalgia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (≤5%), headache (≤5%), insomnia (≤5%), irritability (≤5%), lethargy (≤5%), migraine (≤5%), nervousness (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema, palpitations</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum cholesterol, increased serum prolactin</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria, pollakiuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, extrapyramidal reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolonged QT interval on ECG (Morris 2016), severe ventricular arrhythmia, torsades de pointes (Giudicessi 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dystonia (Dhakal 2014), lupus-like syndrome (Yasue 1986)</p></div>
<div class="block coi drugH1Div" id="F162475"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to domperidone or any component of the formulation; prolactin-releasing pituitary tumor (prolactinoma); known existing prolongation of cardiac conduction intervals, particularly QT; significant electrolyte disturbances; underlying cardiac disease (eg, heart failure); moderate or severe hepatic impairment; patients with GI hemorrhage, mechanical obstruction, or perforation; concomitant use with potent CYP3A4 inhibitors such as azole antifungals (eg, ketoconazole), macrolides (eg, erythromycin), protease inhibitors, or nefazodone; concomitant use with QT-prolonging drugs</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F162459"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Elevated prolactin levels: May increase prolactin levels (dose-dependent response); may be asymptomatic (clinical consequence of chronically elevated prolactin is unknown) or may present symptomatically as galactorrhea, gynecomastia, amenorrhea, or impotence (reversible upon decreasing dose or discontinuing drug). Use is contraindicated in patients with prolactinomas.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer: Use caution when administering to patients with a personal or family history of breast cancer; evidence regarding an association between chronic use of dopamine-receptor antagonists and breast cancer is limited and nonconclusive.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Undergoes extensive hepatic metabolism; use is contraindicated in patients with moderate to severe hepatic impairment; use with caution in mild impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with severe renal impairment; dosage and/or frequency of administration may need adjusted with repeated use and/or long-term therapy. Monitor renal function regularly, particularly with long-term therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Breast milk production stimulant: In 2004, the Food and Drug Administration (FDA) issued a warning recommending that domperidone not be used off-label to increase milk production in breast-feeding women due to safety concerns. Several cases of cardiac arrhythmia, cardiac arrest, and sudden death have been reported in patients receiving intravenous domperidone. The risk of similar adverse events in breast-feeding women is unknown. Domperidone is not available for any use in the United States (except via severe GI disorder IND) and does not have approval for this indication in other countries.</p></div>
<div class="block prod-avail drugH1Div" id="F11233709"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F56512762"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52866650"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p></div>
<div class="block accres drugH1Div" id="F13841022"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Domperidone is available via an Investigational New Drug Application (IND) in the United States for severe GI disorders refractory to standard therapy. For more information on the requirements for the IND, contact the Food and Drug Administration (FDA) at 301-796-3400.</p></div>
<div class="block adm drugH1Div" id="F162472"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: In GI motility disorders, administer 15 to 30 minutes prior to meals and at bedtime if needed. </p></div>
<div class="block use drugH1Div" id="F162471"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>GI motility disorders:</b> Symptomatic management of upper GI motility disorders associated with chronic and subacute gastritis and diabetic gastroparesis</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea/vomiting associated with dopamine-agonist anti-Parkinson agents:</b> Prevention of GI symptoms (eg, nausea, vomiting) associated with use of dopamine-agonist anti-Parkinson agents</p></div>
<div class="block mst drugH1Div" id="F9770161"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Domperidone may be confused with iloperidone, paliperidone</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F162526"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2B6 (minor), CYP2C8 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F162463"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: Domperidone may diminish the therapeutic effect of Bromocriptine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Domperidone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Domperidone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Domperidone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosfomycin: Gastrointestinal Agents (Prokinetic) may decrease the serum concentration of Fosfomycin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: May enhance the QTc-prolonging effect of Domperidone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: May enhance the QTc-prolonging effect of QT-prolonging CYP3A4 Substrates. Management: Do not use lefamulin tablets with QT-prolonging CYP3A4 substrates. Lefamulin prescribing information lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging CYP3A4 Substrates may enhance the QTc-prolonging effect of Levoketoconazole. Levoketoconazole may increase the serum concentration of QT-prolonging CYP3A4 Substrates. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Benzamide Derivatives may enhance the adverse/toxic effect of Levosulpiride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Domperidone. Monoamine Oxidase Inhibitors may diminish the therapeutic effect of Domperidone. Domperidone may diminish the therapeutic effect of Monoamine Oxidase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: Domperidone may enhance the QTc-prolonging effect of Ondansetron.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): Domperidone may enhance the QTc-prolonging effect of Pentamidine (Systemic).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: May increase the serum concentration of QT-prolonging CYP3A4 Substrates. Such increases may lead to a greater risk for proarrhythmic effects and other similar toxicities.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of Domperidone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of Domperidone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): Domperidone may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): Domperidone may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk). QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Domperidone. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Domperidone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): Gastrointestinal Agents (Prokinetic) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triptorelin: Hyperprolactinemic Agents may diminish the therapeutic effect of Triptorelin. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F46106881"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Domperidone serum concentrations may be increased when taken with grapefruit juice. Management: Avoid concurrent use.</p></div>
<div class="block pri drugH1Div" id="F162478"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Outcome data following maternal use of domperidone during pregnancy are limited. Based on available information from observational studies and health care database studies, an increased risk of adverse fetal events has not been observed following maternal use of domperidone in the first trimester (Araujo 2021; Choi 2013; Cottin 2015; Hishinuma 2021; Ishikawa 2022).</p></div>
<div class="block brc drugH1Div" id="F162479"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Domperidone is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of domperidone in breast milk are available from multiple studies (da Silva 2001; Hofmeyr 1983; Knoppert 2013; Krutsch 2023; Wan 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">• A study included 6 mothers of preterm infants (including two sets of twins and four singletons) with a postpartum milk production of &lt;300 mL/day following 2 to 3 weeks of usual interventions to increase milk production. Domperidone was administered in doses of 30 or 60 mg/day in evenly divided doses every 8 hours and breast milk was sampled at intervals over 8 hours following 1 week of therapy. Median concentrations of domperidone in breast milk were 0.28 ng/mL following a 30 mg/day dose and 0.49 ng/mL with the 60 mg/day dose. Using the median milk concentrations, authors of the study calculated the estimated exposure to the breastfeeding infant to be 0.04 mcg/kg/day (relative infant dose 0.012% compared to a weight-adjusted maternal dose of 30 mg/day) or 0.07 mcg/kg/day (relative infant dose 0.009% compared to a weight-adjusted maternal dose of 60 mg/day) (Wan 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">• Domperidone was used in a study of women 14 to 21 days postpartum with a daily milk volume of &lt;500 mL following delivery at &lt;33 weeks' gestation. Patients in this study received oral domperidone 10 mg 3 times a day (n = 8) or 20 mg 3 times a day (n = 7) for 4 weeks. Breast milk was sampled 3, 6, and 8 hours after the maternal dose, between days 10 and 15 of therapy. The highest median milk concentration of domperidone was 6.9 ng/mL, which occurred 3 hours after the 20 mg dose. Mothers did not observe adverse events in the breastfed infants (Knoppert 2013). Using a milk concentration of 6.9 ng/mL, the relative infant dose of domperidone is 0.12% compared to a weight-adjusted maternal dose of 20 mg, providing an estimated daily infant dose via breast milk of 0.001 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">• Breast milk was evaluated in a patient taking domperidone 40 mg four times a day for 7 months. Four breast milk samples were provided over the course of 24 hours, ranging from 6.2 to 8.4 ng/mL. Using the average breast milk concentration (7 ng/mL) authors of the study calculated the relative infant dose of domperidone to be 0.05% compared to the weight-adjusted maternal dose (1.95 mg/kg/day), providing an estimated daily infant dose via breast milk of 0.001 mg/kg/day (Krutsch 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">• One study reported events following maternal use of domperidone 10 mg 3 times daily (n = 45 mothers, 52 infants) or placebo (n = 45 mothers, 51 infants). Two cases of QTc interval change (442 to &gt;500 msec) were noted in newborns in the domperidone group and 1 case in the placebo group after 14 days. There were no symptoms noted in the infants and no treatment was required (Asztalos 2017). Most available studies did not evaluate adverse events in breastfed infants following maternal use of domperidone (Shen 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">• Breastfeeding is not recommended by the manufacturer. However, breastfeeding is generally considered acceptable when the relative infant dose of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone may increase prolactin concentrations and cause galactorrhea and gynecomastia. As such, it has been used off label as a galactagogue in patients with insufficient milk production. Pooled data from available studies note milk production may be increased over placebo (Foong 2020; Grzeskowiak 2018; Osadchy 2012; Paul 2015; Shen 2021; Taylor 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">Case reports describe the use of domperidone (in combination with other therapies) to induce lactation in non–gestational parents, including transgender patients undergoing feminizing hormone therapy, or adoptive patients who wish to breastfeed, and persons who wish to donate breast milk (Al-Mohsen 2021; Lopez-Bassols 2021; Reisman 2018; Schnell 2022; Wamboldt 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Canadian product labeling notes domperidone may be associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death, particularly with doses &gt;30 mg or use in older patients. A retrospective study conducted by linking administrative health databases in Canada found the incidence of ventricular tachycardia or sudden cardiac death in postpartum patients between 15 and 55 years of age taking domperidone to be rare. Postpartum use of domperidone decreased over the study period (2004 to 2017) and any potential increased risk associated with these adverse events was not able to be confirmed. The data collected were not able to limit to only patients using domperidone for lactation but did exclude patients using domperidone prior to pregnancy (Moriello 2021). The risk of adverse cardiac events may be increased in patients with a history of arrythmias or those using concomitant medications that may inhibit the metabolism of domperidone (ABM [Brodribb 2018]).</p>
<p style="text-indent:-2em;margin-left:2em;">Psychiatric symptoms, including insomnia, depression, and anxiety/panic attacks, have been reported in lactating patients upon tapering use of domperidone; suicidal and homicidal ideations have also been reported (Doyle 2018; Majdinasab 2022; Papastergiou 2013; Sharma 2022). Depression and thoughts of infanticide were reported in a patient after self-medicating with domperidone for 3 months to induce lactation after adopting a child. Symptoms improved following discontinuation of domperidone and 2 months of counseling and treatment with an antidepressant. This patient was also grieving the loss of another child. Authors of this case suggest domperidone should be used with caution in patients with previous psychiatric symptoms (Suain Bon 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone is not approved for any indication in the United States. In addition, domperidone is not currently approved in any country as a galactagogue (Sewell 2017). The US Food and Drug Administration (FDA) has issued a warning recommending that domperidone not be used off label to increase milk production in breastfeeding patients due to safety concerns related to cardiac arrhythmias, cardiac arrest, and sudden death (FDA 2004). In Canada where domperidone is approved for other indications, a maximum daily dose has been recommended to decrease the incidence of abnormal heart rhythms and cardiac arrest (Health Canada 2015); some studies evaluating domperidone off label as a galactagogue have used doses higher than the maximum recommended labeled indication (Jantarasaengaram 2012; Knoppert 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for adverse maternal events, a full evaluation for medical causes of low milk supply and nonpharmacologic measures should be considered prior to the use of medications as galactagogues. The Academy of Breastfeeding Medicine does not recommend use of any specific galactagogue due to inconclusive data and potential adverse effects. If use of domperidone is being considered, patients should be screened for a history of cardiac arrhythmias and concurrent use of medications that may increase the risk of arrhythmias. An ECG prior to use and 48 hours after domperidone is initiated may be considered for some patients. Various doses and durations of therapy have been suggested; generally, the maximum effect is observed by 7 to 14 days. The lowest possible dose for the shortest duration of time is recommended. In addition, consider a gradual discontinuation of domperidone (ABM [Brodribb 2018]).</p></div>
<div class="block mop drugH1Div" id="F162467"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function; ECG (baseline and then periodically during therapy)</p></div>
<div class="block pha drugH1Div" id="F162458"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Domperidone has peripheral dopamine receptor blocking properties and does not readily cross the blood-brain barrier. It increases esophageal peristalsis and increases lower esophageal sphincter pressure, increases gastric motility and peristalsis, and enhances gastroduodenal coordination, therefore, facilitating gastric emptying and decreasing small bowel transit time.</p></div>
<div class="block phk drugH1Div" id="F162474"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 93% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic via CYP3A4, N-dealkylation and hydroxylation </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 7 hours (increases to ~21 hours in severe renal impairment)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak serum concentration: 30 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (66%); urine (31%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F162481"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Dompex | Dompy | Domstal | Mododom | Motilium | Motilone | Nausidom | Prokinin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Domperix | Ecuamon | Estocalm | Euciton | Gastrodom | Kinetidom | Moperidona | Motilium | Peridon | Voyou</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Motilium</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo Domperidone | Motilium</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Adegut | Adorex | Anet | Apedom | Apidone | Apuldon | Atidon | Avomit | Benidon | Cosy | Dedom | Deflux | Degut | Domaid | Domar | Domidon | Domilin | Domilux | Domin | Dominaaf | Dominat | Dominol | Domiren | Dompen | Dompi | Domsil | Domstol | Domtec | Don-a | Dopadon | Dopagut | Doperon | Dopon | Doridon | Dudon | Dysnov | Edone | Efodio | Egut | Emedon | Emidom | Eridon | Esogut | Evdom | Gidora | Gutset | Loval | Merin | Motigen | Motigut | Motil | Motilant | Motilex | Motinorm | Motiper | Myodon | Nudon | Omid | Omidon | P-Don | Paridon | Peridone-s | Perigut | Peristal | Predon | Prokinet | Protix | Ridon | Sagdon | Sb dom | Sydon | Tydon | Vave | Vegadon | Vomino | Xepadon | Xeridon</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Docdomperi | Dompephar | Domperidone eurogenerics | Domperidone merck-generics | Domperidone teva generics belgium | Domperitop | Motilium | Noseum | Zilium</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Dulcan | Evidan | Gerdilium | Nauselium | Peridys</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Costi | Motilium</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Domped | Domperidona | Domperix | Domperol | Dompgran | Dompliv | Molidon | Motilium | Motiridona | Peridal | Peridona</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Motilium</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Dulcan | Evidan | Gerdilium | Nauselium | Peridon</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Domperidona | Donegal | Dosin | Idon | Pipran | Restol | Siligaz</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bao tai li tong | Domperid | Heng bang | Kuai ke lin | Li mei lin | Lu de lin | Ma ding lin | Motilium | Wei dong lin | You ma lin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Domperidona | Domperidona winthrop | Domperix | Harmetone | Isedron | Moperid | Norinpep</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Motilium</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Domidon | Domperidon | Domperidon 1 a pharma | Domperidon beta | Motilium</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Gastroflux | Motilium</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dosin | Motilium</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Motilium</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Dompidone | Farcotilium | Gastromatil | Gastromotil | Motilium | Motinorm | Synchro-Git</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Domperidona gamir | Domperidona Pensa | Motilium | Nauzelin</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Domperon</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Biperidys | Domperidone Actavis | Domperidone Almus | Domperidone Arrow | Domperidone arrow | Domperidone biogaran | Domperidone eg | Domperidone g gam | Domperidone gnr | Domperidone irex | Domperidone ivax | Domperidone merck | Domperidone Qualimed | Domperidone Ratiopharm | Domperidone rpg | Domperidone Sandoz | Domperidone Teva | Domperidone Zydus | Motilium | Peridys</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Domilium | Domperidone | Domperidone Arrow | Domperidone kent | Domperidone Sandoz | Motilium | Vivadone</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cilroton</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo Domperidone | Apuldon | Costi | Dompedon | Dompeon | Domper m | Domperdone | Domperidon Stada | Doridone | Eurotilium | Floralin | Genolin | Kantuu | Monell | Motilium | Motione | Naupastad 10 | Neo ridone | Nidolium | Pesdon | Qualidom | Rabugen | Synotilium | Vemetis 10 | Vicktilin | Vicktilium</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Motilium</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Costil | Digestadon | Dom | Dombaz | Dome | Domeran | Dometa | Dometic | Domperidon | Domperidone | Galdom | Galflux | Gerdilium | Grameta | Hufadon | Lexadon | Monell | Motilium | Myori | Nomesis | Novotil | Regit | Rosidon | Tilidon | Vesperum | Vidon | Vomecho | Vomerin | Vometa | Vomidone | Vomistop | Vomitas | Vosedon | Yaridon</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Domerid | Motilium</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Motilium</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acidopar | Aglodom | Aldom | Antem | Babydone | Cezvom | Denosia | Dimpy | Dom | Dom dt | Dom one | Dombax | Domcolic | Domel | Domeron | Domi | Domidone | Domitin | Domnat | Domolic | Dompar | Domped | Domper | Domperi | Domperistal | Dompon | Dompro | Dompy | Domsettler | Domstal | Domstal dt | Domtop | Domup | Domzen | Eldostal | Emidon | Emiges | Eminol | Emitex | Emitin | Emstal | Endopace | Enteridone | Gasidone | Gastractiv | Gastrium | Lupidom | Lydom | Montinorm | Motidom | Motilium m | Motinorm | Motiwin | Nausdan | Nausidome | Nautigo | Perid | Peridon | Prodom | Revert | Shidom | Stopvom | Toyodom | Unistal | Vindome | Vomidom | Vomilium | Vomirax | Vomistop | Zidon</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Domperid in | Domperisam | Motidon | Motiliufay</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Domperidone | Domperidone angenerico | Domperidone Ate | Domperidone copernico | Domperidone eg | Domperidone jet | Domperidone Merck Generics | Domperidone Ratio | Domperidone sandoz | Domperidone Tev | Mod | Motilium | Peridon | Permotil | Riges | Stalcare</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Costi | Dompirid | Motilat | Motilium | Peridon | Prokinin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cobaperidon | Daiteredon | Dalic | Dalic Taiyo | Domperidone | Domperidone nichiiko | Domperidone sawai | Domperin | Drikker | Forimezin | Fuleiya | Hadodolin | Iridollin | Jackmar | Mionazelin | Monlobia | Nasirobin | Nausea | Nausiron | Nauzart | Nauzelin | Nyridone | Perizelin | Peroric | Selovase | Selovase chemiphar | Selovase teisan | Tohmine | Uperidone</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Deflux | Domi | Domperon | Dompex | Domstal | Don a | Esogut | Lockit | Motil | Motilium | Motinorm | Peptomet | Prokinet | Ridon</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alvogen domperidone | Apepsia | Apepsia m | Borium | Borium m | Celltrion domperidone | Coperi | Darida | Dm | Domdon | Domdon m | Dompel | Dompel-m | Dompenyl | Domperidone | Domperidone bkw | Domperidone daewon | Domperiman | Domperin | Domperium m | Dompidone | Dompil | Domprin | Domtan tm | Donpedone | Donpel | Dopadon | Dopemine | Doprium | Emtridon | Feldon t | Gasco | Gasperin | Gasperin m | Gasperine | Gasteline | Gl domperidone | Hamidon | Hamidon m | Hanall domperidone maleate | Kanthidin | Maladon | Malidon | Maradon | Maradon-m | Maridone | Maridone-m | Monadon | Monadorine | Montes | Montes-m | Moparin m | Moperidone | Moperine m | Morem | Morinol | Morinol m | Morium | Motaridon | Motidin | Motildon | Motildon-m | Motilium | Motilium m | Motirem | Motirol | Muvidon | Muvidon m | Ompel | Peldon-t | Pelton | Peridium | Peridom | Perinal | Pesdon | Sama domperidone | Sanperidone | Shinperidone | Sinil domperidone | Soltina | Tameridone | Toriem | Trimodone | Unidon m | Unidone | Unidone m | Union domperidone | Wiroxin | Youngil domperidone maleate</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Domperidon hexal | Dompidone | Dompy | Gastromotil | Mododom | Motilium</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Domidone | Farcotilium | Mododom | Motilat | Motilium | Nauzex | Peridon | Pms Domperidone | Prokinin | Vomistop</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Domstal | Motilium</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Motilium</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Motilium</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Biperidys | Motilium | Nauselium | Peridys | Prokinin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Biolix | Domperidona | Emefren | Motidom | Motilium | Seronex | Seronex lp</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo Domperidone | Dometic | Domil | Dompenyl | Domper | Hovid Smood | Molax-m | Moridone | Motidom | Motidone | Motigut | Motilidone | Motilium | Rabugen | Smood</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Motilium | Reamotil</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Domperidon | Domperidon accord | Domperidon Actavis | Domperidon eureco pharma | Domperidon flx | Domperidon hexal | Domperidon Mdq | Gastrocure | Motilium | San domperidon</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Domperidon hexal | Domperidon Stada | Domperidon teva | Domperidone Winthrop | Motilium | Motilium janssen</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Domperidone viatris | Motilium | Prokinex</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Domperidona | Donamin | Idon | Motilium | Netaf | Peridona</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Abdopen | Accedome | Andiogan | Apuldon | Brudome | Degut | Domilium | Domne | Dompedone | Dompenyl | Domper | Domperidone Flamingo | Domperone | Domphil | Don-a | Dotilium | Dubamol | Flamilium | Gasidone | Gastrium | Gastromec | Gi norm | Gilax | Motilium | Motilux | Motinorm | Pepridon | Peridom | Perilax | Saphridone | Toridon | Vometa | Zydom</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aksotin | Alilium | Almedon | Avomit | Convel v | Costi | Deflux | Do one | Dolium | Domact | Dome One | Dome one | Domel | Domflash | Domflash oro | Domilium | Domino | Domipar | Domlis | Domofit | Domotin | Domozat | Dompedone | Domptilium | Dompy | Dompyrax | Domridone | Domycare | Donits | Donium | Dopedom | Dypin v | Emet | Emidone | Emiset | Emitilium | Emolium | Entevigor | Erolium | Ferrostar | Gasidon | Gastrocure | Gastrocure V | Gastroke | Gutset | Haito | Kinetic | Maprid | Mendon | Milium | Milium v | Molium | Moperium | Moticol | Motidil | Motil | Motilium | Motilium-v | Motim | Motireg | Motiwin | Movedon-v | Mt done | Naudon | Nendone | Nomit | Noslex | Nv-nil | Olidon | Omperin | Optilium | Pelton | Pelton v | Pericid | Perid | Perid M | Peridone | Perilium | Perill | Perimo | Peristal | Plidome | Prokin | Protomic | Rapidone | Relperi | Remato | Residone | Ri One | Ridon | Seldom | Sevidon | Sevidon-v | Stomacol | Stomeze | Talsis | Tilium | Tilium v | Unidon | Unidon V | Veldom | Vometa | Vomilux | Vomistop | Vomitil | Wabdom | Zoramid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Domperidon abz | Motilium</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cinet | Domperidona | Mogasinte | Motilium | Nordonil | Remotil</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Domper | Domperidona 10 mg dutriec | Domperidona 10 mg millet | Domperidona empa | Domperidona quimfa | Emetan | Gastren | Idon | Moperidona | Motilium | Nausefin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Domperide | Dompy | Farcotilium | Gastromotil | Mododom | Mododom OS | Motilat | Motilium | Motilone | Prokinin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Domstal</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Damelium | Domet | Domperidon | Domperidon hexal | Domperidone | Domperidone Teva | Domperidone xantis | Domstal | Motilak | Motilium | Motinorm | Motizhekt | Motogastric | Motonium | Passagix</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Amistop | Mododom | Motilium | Nausidom</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Domperidon ebb</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Dompel | Dompenyl | Domper | Doridone | Gastrium | Mirax | Motilium</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Motilium | Tametil</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Costi</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Auto | Avomit-m | Costi | Dany | Dipace | Dolium | Dom M | Domerdon | Domidone | Domilium | Domilium-m | Dominox | Domon | Domp-m | Dompado | Dompar | Domper m | Domperdone | Domperium m | Domperkress | Domperone | Donox-m | Dopabloc | Doperan | Duodone | Dupegan | Emex | Fadone | Falium | Lima | M tolium | Malum | Meridone | Mirax | Mirax-m | Mocydone | Mocydone-m | Modilin | Modomed | Molax | Molax-m | Molidom | Molum | Moridon | Moridon-m | Moti-m | Moticon | Motidom | Motidom-m | Motidone | Motil | Motilin | Motilium | Motilium m | Motyle | Movelium | Movelium-m | Ninlium | P-tilium | Patilum | Peptomet | Peridium | Peridom-m | Peridone | Perista | Phartilium | Pondperdone | Pondperdone-m | Rabugen | Rabugen-m | Sinolium | Stillium | Teperium | Tolium | Vermadon | Vesperidone | Vomidone | Vomitil-m</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Biperidys | Domper | Dompyrex | Motilium | Peridys | Perilium | Piradium | Vomicalm</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Motilium | Motis</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Costi | D.M.P | Daweison | Dercon | Dompe | Dompedon | Domper | Domperan | Domtodone | Domtoo | Dopine | Dosin | Dotidone | Duoridone | Emetrol | Foselin | Gain-Tonin | Genolin | Kantuu | Ledolium "c.l." | Lidonin | Menton | Mewellin | Modone | Molin | Motaline | Moten | Motilium | Motin | Moturin | Newedon | Nidolium | Pelidone | Peptomet | Peridon | Rotilium | Sutonin | Suweida | Weitul | Wempty | Wyeanin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Domidon | Domperidon | Domperidone | Domrid | Domrid sr | Doprokin | Gastropom apo | Motilium | Motinol | Motinorm | Motoricum | Motorix | Peridon | Perilium</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Domi | Motilium | Motinorm | Prokinet</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Domper | Domperidoll | Domperidona | Domperidona Pellier | Domplexal | Euciton | Motilium</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Domperidona | Dompidom | Dompidon | Domstal | Dosprol | Gasperix | Moperid | Tilium | Tonum</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agimoti | Becadom | Hadilium | Modom s | Moti boston | Motimilum | Vacodomtium</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Bio domperidone | Motilium | Vomidon</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Domidone | Domstal | Lockit | Motinorm</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Domstal | Motilium</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33275500">
<a name="33275500"></a>Al-Mohsen ZA, Frookh Jamal H. Induction of lactation after adoption in a muslim mother with history of breast cancer: a case study. <i>J Hum Lact</i>. 2021;37(1):194-199. doi:10.1177/0890334420976333<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/33275500/pubmed" id="33275500" target="_blank">33275500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apo-Domperidone.2015.03">
<a name="Apo-Domperidone.2015.03"></a>Apo-Domperidone (domperidone) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; March 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33970448">
<a name="33970448"></a>Araujo M, Vabre C, Benevent J, et al. Risk of pregnancy termination and congenital anomalies after domperidone exposure: a study in the EFEMERIS database. <i>Drug Saf</i>. 2021;44(7):787-796. doi:10.1007/s40264-021-01077-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/33970448/pubmed" id="33970448" target="_blank">33970448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28107101">
<a name="28107101"></a>Asztalos EV, Campbell-Yeo M, da Silva OP, Ito S, Kiss A, Knoppert D; EMPOWER Study Collaborative Group. Enhancing human milk production with domperidone in mothers of preterm infants. <i>J Hum Lact</i>. 2017;33(1):181-187. doi:10.1177/0890334416680176<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/28107101/pubmed" id="28107101" target="_blank">28107101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21883386">
<a name="21883386"></a>Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. <i>Br J Clin Pharmacol</i>. 2012;73(3):411-421. doi:10.1111/j.1365-2125.2011.04093.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/21883386/pubmed" id="21883386" target="_blank">21883386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29902083">
<a name="29902083"></a>Brodribb W. ABM Clinical protocol #9: use of galactogogues in initiating or augmenting maternal milk production, second revision 2018. <i>Breastfeed Med</i>. 2018;13(5):307-314. doi:10.1089/bfm.2018.29092.wjb<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/29902083/pubmed" id="29902083" target="_blank">29902083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26117678">
<a name="26117678"></a>Buffery PJ, Strother RM. Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations. <i>N Z Med J</i>. 2015;128(1416):66-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/26117678/pubmed" id="26117678" target="_blank">26117678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23147521">
<a name="23147521"></a>Camilleri M, Parkman HP, Shafi MA, et al. Clinical Guideline: Management of Gastroparesis. <i>Am J Gastroenterol</i>. 2013;108(1):18-37. doi:10.1038/ajg.2012.373<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/23147521/pubmed" id="23147521" target="_blank">23147521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26098410">
<a name="26098410"></a>Chen HL, Hsiao FY. Domperidone, cytochrome P450 3A4 isoenzyme inhibitors and ventricular arrhythmia: a nationwide case-crossover study. <i>Pharmacoepidemiol Drug Saf</i>. 2015;24(8):841-848. doi:10.1002/pds.3814<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/26098410/pubmed" id="26098410" target="_blank">26098410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23445139">
<a name="23445139"></a>Choi JS, Han JY, Ahn HK, et al. Fetal and neonatal outcomes in women taking domperidone during pregnancy. <i>J Obstet Gynaecol</i>. 2013;33(2):160-162. doi:10.3109/01443615.2012.734871<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/23445139/pubmed" id="23445139" target="_blank">23445139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cottin.2015">
<a name="Cottin.2015"></a>Cottin J, Beghim D, Jonville-Bera AP, et al. First trimester exposure to domperidone: a comparative prospective study of exposed infants (abstract). <i>Reproductive Toxicology.</i> 2015;57:217.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34617008">
<a name="34617008"></a>Cowan A, Garg AX, McArthur E, Muanda Tsobo F, Weir MA. Cardiovascular safety of metoclopramide compared to domperidone: A population-based cohort study. <i>J Can Assoc Gastroenterol</i>. 2021;4(5):e110-e119. doi:10.1093/jcag/gwaa041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/34617008/pubmed" id="34617008" target="_blank">34617008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11202662">
<a name="11202662"></a>da Silva OP, Knoppert DC, Angelini MM, et al. Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial. <i>CMAJ</i>. 2001;164(1):17-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/11202662/pubmed" id="11202662" target="_blank">11202662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24973343">
<a name="24973343"></a>Dhakal OP, Dhakal M, Bhandari D. Domperidone-induced dystonia: a rare and troublesome complication. <i>BMJ Case Rep</i>. 2014;2014:bcr2013200282. doi:10.1136/bcr-2013-200282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/24973343/pubmed" id="24973343" target="_blank">24973343</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Domperidone-10 (domperidone) [product monograph]. Laval, Québec: Pro Doc LTÉE; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29090362">
<a name="29090362"></a>Doyle M, Grossman M. Case report: domperidone use as a galactagogue resulting in withdrawal symptoms upon discontinuation. <i>Arch Womens Ment Health</i>. 2018;21(4):461-463. doi:10.1007/s00737-017-0796-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/29090362/pubmed" id="29090362" target="_blank">29090362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11034933">
<a name="11034933"></a>Drolet B, Rousseau G, Daleau P, et al. Domperidone Should Not be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders. <i>Circulation</i>. 2000;102(16):1883-1885. doi:10.1161/01.cir.102.16.1883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/11034933/pubmed" id="11034933" target="_blank">11034933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10638616">
<a name="10638616"></a>Dumitrascu DL, Weinbeck M. Domperidone Versus Metoclopramide in the Treatment of Diabetic Gastroparesis. <i>Am J Gastroenterol</i>. 2000;95(1):316-317. doi:10.1111/j.1572-0241.2000.01721.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/10638616/pubmed" id="10638616" target="_blank">10638616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27182647">
<a name="27182647"></a>Ehrenpreis ED, Roginsky G, Alexoff A, Smith DG. Domperidone is commonly prescribed with QT-interacting drugs: Review of a community-based practice and a postmarketing adverse drug event reporting database. <i>J Clin Gastroenterol</i>. 2017;51(1):56-62. doi:10.1097/MCG.0000000000000543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/27182647/pubmed" id="27182647" target="_blank">27182647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30720577">
<a name="30720577"></a>Field J, Wasilewski M, Bhuta R, et al. Effect of chronic domperidone use on QT interval: A large single center study. <i>J Clin Gastroenterol</i>. 2019;53(9):648-652. doi:10.1097/MCG.0000000000001183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/30720577/pubmed" id="30720577" target="_blank">30720577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32421208">
<a name="32421208"></a>Foong SC, Tan ML, Foong WC, Marasco LA, Ho JJ, Ong JH. Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants. <i>Cochrane Database Syst Rev</i>. 2020;5(5):CD011505. doi:10.1002/14651858.CD011505.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/32421208/pubmed" id="32421208" target="_blank">32421208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441683">
<a name="29441683"></a>Giudicessi JR, Ackerman MJ, Camilleri M. Cardiovascular safety of prokinetic agents: a focus on drug-induced arrhythmias. <i>Neurogastroenterol Motil</i>. 2018;30(6):e13302. doi:10.1111/nmo.13302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/29441683/pubmed" id="29441683" target="_blank">29441683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29469929">
<a name="29469929"></a>Grzeskowiak LE, Smithers LG, Amir LH, Grivell RM. Domperidone for increasing breast milk volume in mothers expressing breast milk for their preterm infants: a systematic review and meta-analysis. <i>BJOG</i>. 2018;125(11):1371-1378. doi:10.1111/1471-0528.15177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/29469929/pubmed" id="29469929" target="_blank">29469929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HealthCanada.1">
<a name="HealthCanada.1"></a>Health Canada. Summary Safety Review. DOMPERIDONE. Serious abnormal heart rhythms and sudden death (cardiac arrest), January 27, 2015. <a href="https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43423a-eng.php#" target="_blank">https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43423a-eng.php#</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33631840">
<a name="33631840"></a>Hishinuma K, Yamane R, Yokoo I, et al. Pregnancy outcome after first trimester exposure to domperidone - an observational cohort study. <i>J Obstet Gynaecol Res</i>. 2021;47(5):1704-1710. doi:10.1111/jog.14709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/33631840/pubmed" id="33631840" target="_blank">33631840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6131323">
<a name="6131323"></a>Hofmeyr GJ, van Iddekinge B. Domperidone and lactation. <i>Lancet</i>. 1983;1(8325):647. doi:10.1016/s0140-6736(83)91818-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/6131323/pubmed" id="6131323" target="_blank">6131323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23188128">
<a name="23188128"></a>Hondeghem LM. Domperidone: limited benefits with significant risk for sudden cardiac death. <i>J Cardiovasc Pharmacol</i>. 2013;61(3):218-225. doi:10.1097/FJC.0b013e31827afd0d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/23188128/pubmed" id="23188128" target="_blank">23188128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34628689">
<a name="34628689"></a>Ishikawa T, Obara T, Akazawa M, et al. Risk of major congenital malformations associated with first-trimester exposure to propulsives: a health administrative database study in Japan. <i>Pharmacoepidemiol Drug Saf</i>. 2022;31(2):196-205. doi:10.1002/pds.5370<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/34628689/pubmed" id="34628689" target="_blank">34628689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22189066">
<a name="22189066"></a>Jantarasaengaram S, Sreewapa P. Effects of domperidone on augmentation of lactation following cesarean delivery at full term. <i>Int J Gynaecol Obstet</i>. 2012;116(3):240-243. doi:10.1016/j.ijgo.2011.10.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/22189066/pubmed" id="22189066" target="_blank">22189066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20652862">
<a name="20652862"></a>Johannes CB, Varas-Lorenzo C, McQuay LJ, Midkiff KD, Fife D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. <i>Pharmacoepidemiol Drug Saf</i>. 2010;19(9):881-888. doi:10.1002/pds.2016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/20652862/pubmed" id="20652862" target="_blank">20652862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22554679">
<a name="22554679"></a>Knoppert DC, Page A, Warren J, et al. The effect of two different domperidone doses on maternal milk production. <i>J Hum Lact</i>. 2013;29(1):38-44. doi:10.1177/0890334412438961<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/22554679/pubmed" id="22554679" target="_blank">22554679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37352416">
<a name="37352416"></a>Krutsch K, Datta P. The transfer of domperidone into human milk remains low at high doses. <i>Breastfeed Med.</i> 2023;18(7):555-556. doi:10.1089/bfm.2023.0108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/37352416/pubmed" id="37352416" target="_blank">37352416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33887977">
<a name="33887977"></a>Lopez-Bassols I, Duke LO, Subramaniam G. Three continents, two fathers, one donor: a non-puerperal relactation case study. <i>J Hum Lact.</i> 2021;37(4):697-702. doi:10.1177/0890334421999327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/33887977/pubmed" id="33887977" target="_blank">33887977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36367713">
<a name="36367713"></a>Majdinasab E, Haque S, Stark A, Krutsch K, Hale TW. Psychiatric manifestations of withdrawal following domperidone used as a galactagogue. <i>Breastfeed Med.</i> 2022;17(12):1018-1024. doi:10.1089/bfm.2022.0190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/36367713/pubmed" id="36367713" target="_blank">36367713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33990364">
<a name="33990364"></a>Moriello C, Paterson JM, Reynier P, et al; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Off-label postpartum use of domperidone in Canada: a multidatabase cohort study. <i>CMAJ Open</i>. 2021;9(2):E500-E509. doi:10.9778/cmajo.20200084<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/33990364/pubmed" id="33990364" target="_blank">33990364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27403002">
<a name="27403002"></a>Morris AD, Chen J, Lau E, Poh J. Domperidone-associated QT interval prolongation in non-oncologic pediatric patients: a review of the literature. <i>Can J Hosp Pharm</i>. 2016;69(3):224-230. doi:10.4212/cjhp.v69i3.1560<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/27403002/pubmed" id="27403002" target="_blank">27403002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Motilium.2021.07">
<a name="Motilium.2021.07"></a>Motilium (domperidone) tablets [prescribing information]. Macquarie Park NSW, Australia: Janssen-Cilag Pty Ltd; July 30, 2021. <a href="https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2009-PI-01258-3&amp;d=20230323172310101" target="_blank">https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2009-PI-01258-3&amp;d=20230323172310101</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22461793">
<a name="22461793"></a>Osadchy A, Moretti ME, Koren G. Effect of domperidone on insufficient lactation in puerperal women: a systematic review and meta-analysis of randomized controlled trials. <i>Obstet Gynecol Int</i>. 2012;2012:642893. doi:10.1155/2012/642893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/22461793/pubmed" id="22461793" target="_blank">22461793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33439512">
<a name="33439512"></a>Ou LB, Moriello C, Douros A, Filion KB. Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: A systematic review and meta-analysis of observational studies. <i>Br J Clin Pharmacol</i>. 2021;87(10):3649-3658. doi:10.1111/bcp.14737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/33439512/pubmed" id="33439512" target="_blank">33439512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23940477">
<a name="23940477"></a>Papastergiou J, Abdallah M, Tran A, Folkins C. Domperidone withdrawal in a breastfeeding woman. <i>Can Pharm J (Ott)</i>. 2013;146(4):210-212. doi:10.1177/1715163513492928<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/23940477/pubmed" id="23940477" target="_blank">23940477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25475074">
<a name="25475074"></a>Paul C, Zénut M, Dorut A, et al. Use of domperidone as a galactagogue drug: a systematic review of the benefit-risk ratio. <i>J Hum Lact</i>. 2015;31(1):57-63. doi:10.1177/0890334414561265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/25475074/pubmed" id="25475074" target="_blank">25475074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PRZ-Domperidone.2021.11">
<a name="PRZ-Domperidone.2021.11"></a>PRZ-Domperidone (domperidone) [product monograph]. Surrey, British Columbia, Canada: Pharmaris Canada Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27062307">
<a name="27062307"></a>Renoux C, Dell'Aniello S, Khairy P, et al; Canadian Network for Observational Drug Effect Studies (CNODES) investigators. Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. <i>Br J Clin Pharmacol</i>. 2016;82(2):461-472. doi:10.1111/bcp.12964<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/27062307/pubmed" id="27062307" target="_blank">27062307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29372185">
<a name="29372185"></a>Reisman T, Goldstein Z. Case report: induced lactation in a transgender woman. <i>Transgend Health</i>. 2018;3(1):24-26. doi:10.1089/trgh.2017.0044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/29372185/pubmed" id="29372185" target="_blank">29372185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20394569">
<a name="20394569"></a>Rossi M, Giorgi G. Domperidone and long QT syndrome. <i>Curr Drug Saf</i>. 2010;5(3):257-262. doi:10.2174/157488610791698334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/20394569/pubmed" id="20394569" target="_blank">20394569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35795891">
<a name="35795891"></a>Schnell A. Successful co-lactation by a queer couple: a case study. <i>J Hum Lact.</i> 2022;38(4):644-650. doi:10.1177/08903344221108733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/35795891/pubmed" id="35795891" target="_blank">35795891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28486375">
<a name="28486375"></a>Sewell CA, Chang CY, Chehab MM, Nguyen CP. Domperidone for lactation: what health care providers need to know. <i>Obstet Gynecol</i>. 2017;129(6):1054-1058. doi:10.1097/AOG.0000000000002033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/28486375/pubmed" id="28486375" target="_blank">28486375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34645378">
<a name="34645378"></a>Sharma V, Sharma S, Doobay M. Domperidone withdrawal in a nursing female with pre-existing psychiatric illness: a case report. <i>Curr Drug Saf</i>. 2022;17(3):278-280. doi:10.2174/1574886316666211013120735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/34645378/pubmed" id="34645378" target="_blank">34645378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33769844">
<a name="33769844"></a>Shen Q, Khan KS, Du MC, Du WW, Ouyang YQ. Efficacy and safety of domperidone and metoclopramide in breastfeeding: a systematic review and meta-analysis. <i>Breastfeed Med</i>. 2021;16(7):516-529. doi:10.1089/bfm.2020.0360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/33769844/pubmed" id="33769844" target="_blank">33769844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27296864">
<a name="27296864"></a>Smolina K, Mintzes B, Hanley GE, Oberlander TF, Morgan SG. The association between domperidone and ventricular arrhythmia in the postpartum period. <i>Pharmacoepidemiol Drug Saf</i>. 2016;25(10):1210-1214. doi:10.1002/pds.4035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/27296864/pubmed" id="27296864" target="_blank">27296864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27861438">
<a name="27861438"></a>Stoetzer C, Voelker M, Doll T, Heineke J, Wegner F, Leffler A. Cardiotoxic antiemetics metoclopramide and domperidone block cardiac voltage-gated Na+ channels. <i>Anesth Analg</i>. 2017;124(1):52-60. doi:10.1213/ANE.0000000000001673<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/27861438/pubmed" id="27861438" target="_blank">27861438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35793516">
<a name="35793516"></a>Suain Bon R, Mahmud AA. Domperidone use as a galactagogue and infanticide ideation: a case report.<i> Breastfeed Med.</i> 2022;17(8):698-701. doi:10.1089/bfm.2022.0016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/35793516/pubmed" id="35793516" target="_blank">35793516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30481478">
<a name="30481478"></a>Taylor A, Logan G, Twells L, Newhook LA. Human milk expression after domperidone treatment in postpartum women: a systematic review and meta-analysis of randomized controlled trials. <i>J Hum Lact</i>. 2019;35(3):501-509. doi:10.1177/0890334418812069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/30481478/pubmed" id="30481478" target="_blank">30481478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2004">
<a name="FDA.2004"></a>US Food and Drug Administration (FDA). FDA Talk Paper: FDA warns against women using unapproved drug, domperidone, to increase milk production. Published June 7, 2004. Accessed October 28, 2021. <a href="https://www.fda.gov/drugs/information-drug-class/fda-talk-paper-fda-warns-against-women-using-unapproved-drug-domperidone-increase-milk-production" target="_blank">https://www.fda.gov/drugs/information-drug-class/fda-talk-paper-fda-warns-against-women-using-unapproved-drug-domperidone-increase-milk-production</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20925438">
<a name="20925438"></a>van Noord C, Dieleman JP, van Herpen G, Verhamme K, Sturkenboom MC. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. <i>Drug Saf</i>. 2010;33(11):1003-14. doi:10.2165/11536840-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/20925438/pubmed" id="20925438" target="_blank">20925438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33513241">
<a name="33513241"></a>Wamboldt R, Shuster S, Sidhu BS. Lactation induction in a transgender woman wanting to breastfeed: case report. <i>J Clin Endocrinol Metab</i>. 2021;106(5):e2047-e2052. doi:10.1210/clinem/dgaa976<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/33513241/pubmed" id="33513241" target="_blank">33513241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18507654">
<a name="18507654"></a>Wan EW, Davey K, Page-Sharp M, Hartmann PE, Simmer K, Ilett KF. Dose-effect study of domperidone as a galactagogue in preterm mothers with insufficient milk supply, and its transfer into milk. <i>Br J Clin Pharmacol</i>. 2008;66(2):283-289. doi:10.1111/j.1365-2125.2008.03207.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/18507654/pubmed" id="18507654" target="_blank">18507654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28843456">
<a name="28843456"></a>Wilcock A, Charlesworth S, Twycross R, et al. Prescribing non-opioid drugs in end-stage kidney disease. <i>J Pain Symptom Manage</i>. 2017;54(5):776-787. doi:10.1016/j.jpainsymman.2017.08.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/28843456/pubmed" id="28843456" target="_blank">28843456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3540058">
<a name="3540058"></a>Yasue T, Nitta Y. Domperidone-induced systemic lupus-like syndrome. <i>J Dermatol</i>. 1986;13(4):293-296. doi:10.1111/j.1346-8138.1986.tb02943.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/3540058/pubmed" id="3540058" target="_blank">3540058</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8777 Version 236.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
